Introduction:Amiodarone is an antiarrhythmic drug widely used to treat and prevent supraventricular and ventricular arrhythmias.However, it can be associated with various adverse events.Few studies have been conducted in Colombia on amiodarone adverse events.Objective: To determine the demographic, clinical and pharmacological characteristics associated with adverse events in patients on amiodarone at a cardiovascular clinic in the city of Medellín.Materials and method: A retrospective, observational, analytical cohort study was conducted through a chart review of patients treated with amiodarone from 2008 to 2021.Univariate, bivariate and multivariate analyses were performed using binomial logistic regression.Results: A total of 553 medical charts were reviewed, 221 of which met the eligibility criteria.The mean age was 63 years, with a predominance of males (57.5%).The majority had multimorbidity (73.3%), and the most common diagnosis for prescribing amiodarone was atrial fibrillation (84.4%).Altogether, 71 patients (32.1%) were reported to have amiodarone-related adverse events, with the most frequent being cardiovascular events (43.7%), followed by thyroid (29.6%) and ophthalmological (10%) events.The variable that was associated with amiodarone-related adverse events was multimorbidity (adjusted relative risk [RR] 1.65;95% CI: 1.02-2.25;p = 0.039).Conclusions: Amiodarone adverse events were common.The characteristic that explains 16.8% (Nagelkerke's R 2 [R² N ]) of the adverse events was multimorbidity, and the majority of the patients required treatment suspension.